Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & Administrative
Others
Ratios

Pasithea Therapeutics (KTTA) EBIT (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed EBIT for 4 consecutive years, with -$3.3 million as the latest value for Q4 2024.

  • Quarterly EBIT rose 36.69% to -$3.3 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$14.2 million through Dec 2024, up 10.82% year-over-year, with the annual reading at -$20.9 million for FY2025, 46.37% down from the prior year.
  • EBIT hit -$3.3 million in Q4 2024 for Pasithea Therapeutics, down from -$3.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$549609.0 in Q1 2021 to a low of -$5.1 million in Q4 2023.
  • Historically, EBIT has averaged -$3.0 million across 4 years, with a median of -$3.2 million in 2023.
  • Biggest five-year swings in EBIT: plummeted 337.5% in 2022 and later surged 36.69% in 2024.
  • Year by year, EBIT stood at -$2.0 million in 2021, then tumbled by 106.66% to -$4.0 million in 2022, then dropped by 27.36% to -$5.1 million in 2023, then soared by 36.69% to -$3.3 million in 2024.
  • Business Quant data shows EBIT for KTTA at -$3.3 million in Q4 2024, -$3.0 million in Q3 2024, and -$3.9 million in Q2 2024.